The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1604
August 10, 2020
View Complete Issue         Table of Contents 2019 
IV Artesunate for Severe Malaria
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
IV Artesunate for Severe Malaria
August 10, 2020 (Issue: 1604)
Artesunate for injection (Amivas LLC), a semi-synthetic artemisinin derivative, is now approved by the FDA for initial (induction) treatment of severe malaria in children and adults. It has been available from the CDC on a compassionate use basis...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: IV Artesunate for Severe Malaria
Article code: 1604a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.